Flotetuzumab

Phase 3Monoclonal antibody

Flotetuzumab is one of 48 small molecule programs targeting Recurrent Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Acute Myeloid LeukemiaActive, not recruiting

SchizophreniaActive, not recruiting

Recurrent Acute Myeloid LeukemiaPhase 1

Active, not recruiting

SchizophreniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Flotetuzumab

Bristol-Myers Squibb

Phase 3

1 2

Resotran

Takeda

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Recurrent Acute Myeloid Leukemia

NCT04158739

Clinical

Trials by Indication[1]

ESS2 trials

Flotetuzumab Expanded Access Program

No longer available·MMacroGenics··NCT04678466

Study to Assess an Interphase Cycle With Flotetuzumab.

Withdrawn·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT05063123

Myelodysplastic Syndrome1 trial

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Terminated·WWashington University School of Medicine·Phase 2·NCT04582864·11 enrolled

AML1 trial

Post-transplant Flotetuzumab for AML

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT05506956·3 enrolled

Recurrent Acute Myeloid Leukemia1 trial

A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 1·NCT04158739·16 enrolled

Schizophrenia1 trial

EMERGE-3: KarXT in Acute Schizophrenia

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04681105·580 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Flotetuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Flotetuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Flotetuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Flotetuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

ESS2 trials

Myelodysplastic Syndrome1 trial

AML1 trial

Recurrent Acute Myeloid Leukemia1 trial

Schizophrenia1 trial

References

Drug Info

Quick Facts

Related News